Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03244683 | A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery(INSPIRE) | terminated | N/A | 8 | Ohio State UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT02921737 | TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) | terminated | Phase 2 | 7 | University of FloridaOTHER | 1 | Feb 4, 2021 |
| clinicaltrials |
| NCT03585062 | Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer | terminated | Phase 2 | 40 | Zhejiang Provincial People's HospitalOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00003531 | Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01938716 | Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy | terminated | N/A | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00493441 | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | terminated | Phase 2 | 28 | Vertex Pharmaceuticals IncorporatedINDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT00429858 | Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer | terminated | Phase 2 | 21 | Andrew KoOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT03600623 | Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer | terminated | Early Phase 1 | 25 | University of Alabama at BirminghamOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03469258 | Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02333409 | Acupuncture for Pain Control in Patients With Inoperable Pancreatic Cancer | terminated | N/A | 1 | Chinese University of Hong KongOTHER | 1 | Jul 17, 2020 | clinicaltrials |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | terminated | Early Phase 1 | 2 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT00614601 | Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer | terminated | Phase 2 | 9 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01836432 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer(PILLAR) | terminated | Phase 3 | 302 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02405585 | Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 10 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02682082 | EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer(EUS-CPN) | terminated | N/A | 22 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT03286062 | VM110 in Detection of Microscopic Tumors: A Phase I Study | terminated | Phase 1 | 1 | Fox Chase Cancer CenterOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | terminated | Phase 2 | 23 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2020 | clinicaltrials |
| NCT03531125 | Gene Expression in Pancreatic Cancer(NEOPANC-01) | terminated | — | 9 | University of OxfordOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03277209 | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas | terminated | Phase 1 | 2 | Weill Medical College of Cornell UniversityOTHER | 2 | Mar 2, 2020 | clinicaltrials |
| NCT02926040 | Quality of Life After in Situ IRE in Locally Advanced Pancreatic Cancer(IRE Qol) | terminated | — | 14 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT02952859 | Impact of Margin-accentuation IRE in Pancreatic Cancer(IRE Marg) | terminated | — | 26 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT03069599 | Immune Response After Pancreatic Cancer Treatment(IRE Immuno) | terminated | — | 38 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT03471468 | Kinetics of Microparticles Under Chemotherapy in Patients With Gastric or Pancreatic Cancer(DOMICA) | terminated | N/A | 3 | Poitiers University HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT02921646 | Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer(EnergiePancrea) | terminated | N/A | 8 | Center Eugene MarquisOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00394602 | Chemoradiation-Induced Nausea and Emesis: Quality of Life | terminated | — | 207 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT02465983 | Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | terminated | Phase 1 | 4 | University of PennsylvaniaOTHER | 1 | Dec 16, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01240304 | A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | University of ArkansasOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02166190 | RFA RCT for Pancreatic or Bile Duct Cancer(RFARCT) | terminated | N/A | 8 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT00414570 | An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs | terminated | Early Phase 1 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02570711 | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | terminated | Phase 2 | 3 | Acerta Pharma BVINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | terminated | Early Phase 1 | 7 | PH Research, S.L.OTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) | terminated | Phase 1 | 30 | The Cooper Health SystemOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery | terminated | Phase 1 | 6 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT01314027 | Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer | terminated | Phase 3 | 38 | University of ZurichOTHER | 4 | Jul 25, 2019 | clinicaltrials |
| NCT02404363 | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy(PANCREADOGREL) | terminated | Phase 3 | 39 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | terminated | Phase 2 | 9 | CCTU- Cancer ThemeOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01313416 | Gemcitabine and CT-011 for Resected Pancreatic Cancer | terminated | Phase 2 | 2 | Augusta UniversityOTHER | 1 | Jul 10, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2021source: clinicaltrials